Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Documented informed consent from legal guardian~2. 0-84 days postnatal age at time of first study dose or when enrolled into the non-intervention cohort.~3. Clinical diagnosis of superficial cutaneous or mucosal infantile hemangioma (must include all of the following):~   1. Superficial lesion in the dermis~  2. Thin \<2 mm in thickness~  3. Small \>=5 cm at its longest dimension and \<=10cm2~  4. Involves skin or keratinized mucosa~Exclusion Criteria~1. History of previous treatment with any pharmacologic or laser therapy for IH~2. Ongoing therapy with an oral beta blocker or oral corticosteroid (e.g., cardiac arrhythmia, adrenal insufficiency, upper airway obstruction, tetralogy of fallot (TOF), hypertension, reactive airways disease)~3. IH that requires systemic therapy (defined by dynamic complication scale \>3)~4. IH of the non-keratinized mucosa~5. Infants with more than one hemangioma that requires therapy~6. Hemodynamically significant cardiovascular disease, as determined by the investigator~7. Known allergy to beta blockers or vehicle~8. Heart rate \<100 beats per minute at screening visit~9. Known prenatal or postnatal diagnosis of 2nd/3rd degree atrioventricular block~10. History of Reactive Airways Disease (RAD)~11. Any condition which would make the participant, in the opinion of the investigator unsuitable for the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 84 Days
- Healthy Volunteers: f

Study Arms:
- 0.25% Timolol Treatment (Type: EXPERIMENTAL): Subjects assigned to this arm will be randomized to 0.25% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.25% timolol they will be changed to 0.5% timolol.
- 0.5% Timolol Treatment (Type: EXPERIMENTAL): Subjects assigned to this arm will be randomized to 0.5% timolol for 180 days. If during the 180 days the subject is considered a treatment failure, the subject will be unblinded. If the subject is on 0.5% timolol the treating physician will decide to either continue 0.5% timolol or withdraw the subject and begin an alternative treatment.
- Non-Intervention Group (Type: NO_INTERVENTION): Subjects assigned to this group will not receive treatment. The subject will only be photographed on the same schedule as the intervention group.

Based on this trial design, predict the completion outcome and termination type (if applicable).